Top Journalists
Top Outlets
Are you a Prowly user?
Log in here
Top Journalists
>
Leah Kuntz
Leah Kuntz
Editor at
Psychiatric Times
Contact this person
Email address
l*****@*******.com
Get email address
Influence score
30
Location
United States
Languages
English
Covering topics
Health & Medicine
View more media outlets and journalists by signing up to AI PR
View latest data and reach out all from one place
Sign up to AI PR Toolkit
Recent Articles
psychiatrictimes.com
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Dist...
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
9 days ago
psychiatrictimes.com
Before Treating Excessive Sleepiness, Make Sure You Know What You'r...
Before Treating Excessive Sleepiness, Make Sure You Know What You're Treating
14 days ago
psychiatrictimes.com
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for...
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
24 days ago
psychiatrictimes.com
New Analyses of HLP003 for the Adjunctive Treatment of MDD
New Analyses of HLP003 for the Adjunctive Treatment of MDD
25 days ago
psychiatrictimes.com
New Real-World Data Supporting Cariprazine for MDD and Bipolar I De...
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
28 days ago
psychiatrictimes.com
Insights on the New Adult ADHD Guidelines: A Conversation With the ...
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
about 1 month ago
psychiatrictimes.com
Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depre...
Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
about 1 month ago
psychiatrictimes.com
Positive Topline Results From Phase 3 Panorama Study of DT120 ODT i...
Positive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
about 1 month ago
psychiatrictimes.com
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybi...
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
about 1 month ago
psychiatrictimes.com
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The...
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
about 1 month ago
psychiatrictimes.com
Presenting Our September 2026 Theme: Depressive Disorders
Presenting Our September 2026 Theme: Depressive Disorders
about 2 months ago